Newsroom

15-07-21 - Event

mint & pepper - free places in the workshop DanceBots for Girls

Are you still looking for an exciting vacation program for your daughter? mint & pepper offers a workshop at the end of July. The workshop is aimed at girls aged 10-14. In this two-day course, the girls learn to build a dancing robot. The electronic components are soldered onto a circuit board, the mechanical parts are assembled and the robot is decorated. Afterwards, a choreography is created using special software, which the robot then dances. The DanceBot can of course be taken home after the workshop.

read more

12-07-21 - Media Coverage

Computerworld.ch - Technik für die neue Arbeitswelt

The pandemic is putting companies to the test. However, digital tools are helping significantly to master the challenges of the crisis. This is also true for the solution of the Swiss start-up Seervision, as the online magazine computerwelt.ch now highlights. Seervision, which is currently funded by Wyss Zurich, offers software that automates cameras in studios. It makes use of artificial intelligence, image recognition and mathematical prediction models. In this way, the movements of a person in the picture are to be anticipated and the cameras can be panned as if they were being operated by a cameraman. The software is particularly suitable for companies that do not want to do without professional broadcasting, even if the budget is small and the know-how is not available. Read the entire report (in German).

read more

07-07-21 - News

Startupticker.ch - Report sheds light on the strengths of the start-up driven Swiss drone industry

Voliro and Wingtra - two Wyss Zurich projects - are mentioned in the first Swiss Drone Industry Report. The publication reveils that Switzerland is an attractive place for innovative drone companies. A high number of start-ups are active in numerous niche markets and ensure a high export share due to innovations.

read more

06-07-21 - News

hemotune awarded with Innosuisse Certificate

Congratulations to hemotune on this success! The Innosuisse certificate is associated with many benefits for start-ups: The certificate reflects remarkable progress made during the program and it confirms that the start-up is ready for sustainable growth. In addition, start-ups also benefit from increased awareness, greater attractiveness for potential investors, and access to additional events, initiatives, and programs, among other things.

read more

02-07-21 - News

BURNS OPEN - Further proof of principle for denovoSkin on a massive burn with a one-year follow-up

The latest edition of Burns Open, the peer reviewed international journal, has published the case report of a 14-year-old who sustained deep flame burns involving 95% total body surface area burn (TBSA). As part of the treatment at the University Children’s Hospital Zurich, the patient received CUTISS’s denovoSkin grafts (12% TBSA) alongside other treatments.

read more

24-06-21 - Press Release

CUTISS develops world`s first machine to produce personalized human tissue

CUTISS AG, a Swiss clinical-stage life science company focused on regenerative medicine of the skin and tissue engineering, has unveiled the world's first automated machine for the production of customized skin tissue grafts for adults and children with severe skin injuries, such as deep burns. (Read the official Press Release in German). Congratulations to CUTISS for this world-first innovation!

read more

08-06-21 - Press Release

University of Zurich - Approval for New Alzheimer´s Drug Development at UZH

Congratulations to Wyss Zurich Core Faculty Member Roger Nitsch as well as Christoph Hock, and the entire team for this great achievement. They discovered the substance aducanumab that has now been approved for use in the United States as a treatment for Alzheimer`s disease. Read the press release of the University of Zurich here.

read more

01-06-21 - News

Wyss Zurich welcomes the news that Novartis has signed a cooperation agreement and an option to acquire Cellerys

The UZH spin-off Cellerys AG is conducting research on an innovative therapy to treat multiple sclerosis (MS). This therapy has the potential to delay the progression of the disease. Wyss Zurich has funded the project, named ETIMSred, from October 2015 to June 2021. During this time, a successful Phase 1 clinical trial was conducted at the University Hospital Zurich. Novartis will now support further development of the therapy, which is currently in a Phase 2 clinical trial. “This development shows that the Wyss Zurich mission – to bridge the Valley of death by supporting excellent research from bench-to-bedside – works and that our projects can successfully move on after acceleration at Wyss Zurich," states Professor Simon P. Hoerstrup, Founding Co-Director of Wyss Zurich. Read the official media release from Novartis (in German) here

read more

31-05-21 - Press Release

Wyss Zurich alumni project HYLOMORPH announces successful completion of first phase in human clinical trial

Hylomorph, a clinical stage MedTech startup company, spin-off of the Swiss Federal Institute of Technology (ETH Zurich), announces the positive evaluation by an independent Data Safety Monitoring Board of the clinical safety for their product Hylomate.

read more

25-05-21 - Media Coverage

startupticker.ch - CUTISS´denovoSkin first large scale transplantation delivers proof of principle

Wyss Zurich has been supporting the denovoSkin project since 2017. Now startupticker publishes a big development milestone of the project and its startup company CUTISS in the treatment of patients with severe burns: "For the first time, CUTISS succeeded in transplanting 1,626 cm2 of denovoSkin in a child patient with 95 percent total body surface area deep flame burn. This achievement further validates that the company's bio-engineered skin graft has the potential to help substantially in severe and acute burns.

read more